Cibc World Market Inc. Reduces Stake in CVS Health Corporation $CVS

Cibc World Market Inc. lowered its stake in CVS Health Corporation (NYSE:CVS) by 1.3% in the 4th quarter, Holdings Channel reports. The firm owned 523,735 shares of the pharmacy operator’s stock after selling 6,929 shares during the quarter. Cibc World Market Inc.’s holdings in CVS Health were worth $41,564,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Alteri Wealth LLC increased its holdings in CVS Health by 3.2% during the 3rd quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after acquiring an additional 131 shares during the period. TOWER TRUST & INVESTMENT Co boosted its holdings in CVS Health by 0.8% in the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after purchasing an additional 132 shares during the period. Holistic Financial Partners grew its position in shares of CVS Health by 4.1% during the 3rd quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock valued at $256,000 after purchasing an additional 133 shares in the last quarter. CYBER HORNET ETFs LLC grew its position in shares of CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after purchasing an additional 134 shares in the last quarter. Finally, LS Investment Advisors LLC increased its holdings in shares of CVS Health by 3.9% in the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after purchasing an additional 135 shares during the period. 80.66% of the stock is currently owned by institutional investors.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health was upgraded to Zacks Rank #2 (Buy), signaling improved earnings optimism and adding to the case for near-term upside. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with reports noting an average recommendation of “Moderate Buy” for CVS, reinforcing investor confidence in the name. Article Title
• Positive Sentiment: Rallying health insurers such as Humana, UnitedHealth, and Cigna on hopes of softer medical cost trends is boosting sentiment across the sector and likely supporting CVS shares as well. Article Title
• Neutral Sentiment: CVS also highlighted community and behavioral-health initiatives, including senior affordable housing and expanded mental health access, which are positive for its long-term brand but unlikely to move the stock much in the short term. Article Title
• Neutral Sentiment: Broader market news, including futures weakness ahead of the jobs report, appears to be a macro backdrop rather than a CVS-specific driver. Article Title

CVS Health Trading Up 3.8%

NYSE CVS opened at $94.84 on Friday. The stock’s 50-day simple moving average is $83.65 and its two-hundred day simple moving average is $79.91. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $98.43. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $121.00 billion, a price-to-earnings ratio of 41.78, a PEG ratio of 0.89 and a beta of 0.62.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Research analysts forecast that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.8%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,441,551 shares of company stock valued at $323,703,977. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on CVS. HSBC lifted their price objective on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday, May 5th. Argus raised their price target on CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, May 14th. Barclays boosted their price objective on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a report on Tuesday, May 26th. UBS Group upped their price objective on shares of CVS Health from $97.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Finally, Wells Fargo & Company raised their target price on shares of CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.88.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.